Piper Jaffray Reiterates Overweight Rating on Impax Labs
According to Piper Jaffray, Impax Laboratories (NASDAQ: IPXL) Overweight rating is reiterated.
Piper Jaffray said that it met with Impax senior management yesterday, and came away with increased confidence that management is tracking to a timely resolution of the manufacturing issues at its Hayward, CA facility (i.e., before March 1). “We reiterate our Overweight rating and $32 price target.”
Impax Laboratories closed yesterday at $19.92.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.